New adult ART guidelines



Graeme Meintjes

University of Cape Town Imperial College London Imperial College London





Port Alfred, 30 May 2015, SA HIV Clinicians Society CME

National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults

24 December 2014



1

GUIDELINE Adult antiretroviral therapy auidelines 2014

By the Southern African HIV Clinicians Society

G Meinties (chairpers

I Black, F Conradie, V Cox, S Dlamini, J Fabian, G Maartens, T Manzini, M Mathe, C Menezes, M Moorhouse, Y Moosa J Nash, C Orrell, Y Pakade, F Venter, D Wilson (expert panel members)

Correspondence: Southern African HIV Clinicians Society (sahivsoc@sahivsoc.org)

Disclaimer: Specific recommendations provided here are intended only as a guide to clinical management, based on expert consensus and best current evidence. Treatment decisions for patients should be made by their responsible clinicians, with due consideration for individual circumstances. The most current version of this document should always be consulted.

These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2012. Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern Africa has continued. Cohort studies from the region show excellent clinical outcomes; however, ART is still being initiated late (in advanced disease) in some patients, resulting in relatively high early mortality rates. New data on antiretroviral drugs have become available. Although currently few, there are patients in the region who are failing protease-inhibitor-based second-line regimens. To address this, guidelines on third-line therapy have been expanded.

S Afr I HIV Med 2014;15(4):121-143. DOI:10.7196/SAIHIVMED.1130



1. Key principles guidelines are available internationally, the

principles underpinned the writing process:

Africa were included

programmes, considering that many patients transition expectancy.[1] between the two sectors for treatment.

• While it is acknowledged that certain recommendations are **3. Standard of care** aspirational for poorly resourced settings, the unavailability Maximally suppressive ART regimens should be used in HIVproviding ART to those in need.

randomised community studies are awaited.

2. Goals of ART

The primary goals of ART are to: · improve quality of life · reduce HIV-related morbidity and mortality

· provide maximal and durable suppression of viral load (VL) While many antiretroviral therapy (ART) • restore and/or preserve immune function.

current guidelines have been written to add- These goals are achieved by suppressing viral replication ress issues relevant to southern Africa. The following general completely for as long as possible, using well-tolerated and sustainable treatment taken with good adherence. With · South Africa (SA) is a middle-income country, whereas prolonged viral suppression, the CD4' lymphocyte count certain other countries in the region are low-income usually increases, which is accompanied by a restoration of countries; therefore, affordability was taken into account. pathogen-specific immune function. For most patients, this Only treatment and diagnostic options available in southern results in a dramatic reduction in the risk of HIV-associated morbidity and mortality. It is still unclear whether immune · We recognised the need to bridge the gap in treatment function ever returns to full normality. Long-term cohorts show recommendations between public and private sector that patients who adhere well to ART have a near-normal life

of diagnostic/monitoring tests should not pose a barrier to positive individuals to obtain the best results and to prevent resistance. However, non-suppressive regimens have a role There has been a shift to view ART as a means of HIV prevent in HIV prevention, e.g. in the prevention of mother-to-child ion. The clinical trial evidence base for this exists for transmission (PMTCT) (infant prophylaxis), in post-exposure serodiscordant couples; recommendations in this regard prophylaxis (PEP) for healthcare workers following certain low are included in these guidelines and additional data from risk occupational exposures, and in pre-exposure prophylaxis (PrEP). Furthermore, these regimens are probably effective in HIV-negative individuals following low-risk sexual exposures. For further guidance see:

Southern African HIV Clinicians Society. Post-exposure prophylaxis. S Afr J HIV Med 2008;9(3):36-45. (An update will be published in 2015.)

DECEMBER 2014 Vol 15 No 4 SA IHIVMED 121

OUTLINE


- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

OUTLINE


- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

When to start ART?

- In 2013 the WHO increased the CD4 count threshold for starting ART to 500
- Also included all patients with TB, hepatitis B, pregnant women and HIV+ partner in serodiscordant couple as eligible



Number of people eligible for antiretroviral therapy in lowand middle-income countries based on the epidemic and response status at the end of 2012



Updated fig 1.23 (Global update on HIV treatment 2013: results, impact and opportunities: WHO report in partnership with UNICEF and UNAIDS, page 41).



Clinical diagnoses (irrespective of CD4 courtsWHO clinical stage 3 and 4 [†] ART recommendedOther severe HIV-related disorders, e.g.:‡ART recommendedImmune thrombocytopenia Thrombotic thrombocytopenic purpura Rolymyositis Lymphocytic interstitial pneumonitisART recommendedNon HIV-related disorders:§ART recommendedMalignancies (excluding localised malignancies) Hepatitis B [¶] Hepatitis CART recommendedAny condition requiring long-term immunosuppressive therapyART recommended CD4 counts ART recommended S30 cells/µl ART recommended 350-500 cells/µl (two counts in this range)ART recommended if patient ready and motivated to start >500 cells/µl Defer ART HV-infected partner in serodiscordant reitorship Offer ART and discuss safe sex (discussion must involve both partners)	Table 3. Indications for ART*				
Other severe HIV-related disorders, e.g.:‡ ART recommended Immune thrombocytopenia ART recommended Thrombotic thrombocytopenic purpura ART recommended Polymyositis Lymphocytic interstitial pneumonitis ART recommended Non HIV-related disorders:\$ ART recommended Malignancies (excluding localised ART recommended malignancies) Hepatitis B¶ Hepatitis C ART recommended Any condition requiring long-term ART recommended immunosuppressive therapy ART recommended S50-cells/µl ART recommended 350-500 cells/µl ART recommended if patient ready and motivated to start >500 cells/µl Defer ART HIV-infected partner in serodiscordant relationship Offer ART and discuss safe sex	Clinical diagnoses (irrespective of CD4 count)				
Immune thrombocytopenia Thrombotic thrombocytopenic purpura Polymyositis Lymphocytic interstitial pneumonitis Non HIV-related disorders:\$ Malignancies (excluding localised malignancies) Hepatitis B¶ Hepatitis C Any condition requiring long-term immunosuppressive therapy CD4 counts <350 cells/µl	WHO clinical stage 3 and 4 [†]	ART recommended			
Thrombotic thrombocytopenic purpura Polymyositis Lymphocytic interstitial pneumonitisART recommendedNon HIV-related disorders:\$ Malignancies (excluding localised malignancies)ART recommendedHepatitis B¶ Hepatitis CART recommendedAny condition requiring long-term immunosuppressive therapyART recommendedCD4 counts<350 cells/µl	Other severe HIV-related disorders, e.g.: [‡]	ART recommended			
Polymyositis Lymphocytic interstitial pneumonitisART recommendedNon HIV-related disorders:\$ Malignancies (excluding localised malignancies)ART recommendedHepatitis B¶ Hepatitis CART recommendedAny condition requiring long-term immunosuppressive therapyART recommendedCD4 counts<350 cells/µl	Immune thrombocytopenia				
pneumonitisNon HIV-related disorders:\$ Malignancies (excluding localised malignancies)ART recommendedHepatitis B¶ Hepatitis CART recommendedAny condition requiring long-term immunosuppressive therapyART recommendedCD4 counts<350 cells/µl	Polymyositis				
Malignancies (excluding localised malignancies) Image: malignancies (excluding localised malignancies) Hepatitis B¶ Image: malignancies (excluding long-term immunosuppressive therapy Any condition requiring long-term immunosuppressive therapy ART recommended CD4 counts ART recommended <350 cells/µl					
Hepatitis CAny condition requiring long-term immunosuppressive therapyART recommendedCD4 countsART recommended<350 cells/µl	Malignancies (excluding localised	ART recommended			
Any condition requiring long-term immunosuppressive therapyART recommendedCD4 countsART recommended<350 cells/µl	Hepatitis B¶				
immunosuppressive therapy ART recommended CD4 counts ART recommended <350 cells/µl	Hepatitis C				
<350 cells/µl		ART recommended			
350-500 cells/µl (two counts in this range) ART recommended if patient ready and motivated to start >500 cells/µl Defer ART HIV-infected partner in serodiscordant relationship Offer ART and discuss safe sex	CD4 counts				
>500 cells/μl Defer ART HIV-infected partner in serodiscordant relationship Regardless of CD4 count or clinical Offer ART and discuss safe sex	<350 cells/µl	ART recommended			
HIV-infected partner in serodiscordant relationship Regardless of CD4 count or clinical diagnoses	350-500 cells/μl (two counts in this range)				
Regardless of CD4 count or clinical Offer ART and discuss safe sex	<mark>>500 cells/µl</mark>	Defer ART			
diagnosos	HIV-infected partner in serodiscordant relationship				
diagnoses (discussion must involve both partners)		Offer ART and discuss safe sex			
	diagnoses	(discussion must involve both partners)			

HIV seroconversion added as indication for ART

SA HIV Clinicians Society 2014

SA DOH Guidelines Implemented from 1 Jan 2015

Eligible to start ART

CD4 count \leq 500 cells/µl irrespective of clinical stage (Prioritise those with CD4 <350 cells/µl)

OR

Severe or advanced HIV disease (WHO clinical stage 3 or 4), regardless of CD4 count

OR

Irrespective of CD4 count or clinical stage:

- Active TB disease (including drug-resistant and EPTB)
- Pregnant and breastfeeding women who are HIV-positive
- Known hepatitis B viral (HBV)co-infection
- Prioritise those with CD4 <350 cells/µl or advanced HIV disease



Prevention of HIV-1 Infection with Early Antiretroviral Therapy

HPTN 052 trial


Botswana, Brazil, India, Kenya, Malawi, SA, Thailand, Zimbabwe, USA

1736 serodiscordant, sexually active couples with HIV+ partner having CD4 350-550 randomised 1:1 to:

- Immediate ART
- Delay ART until CD4 ≤ 250 or Stage 4 event

Cohen, NEJM 2011;365:493


Early ART reduced HIV transmission




Cohen, NEJM 2011;365:493

ART scale-up associated with lower HIV incidence in rural KZN

- 16,667 HIV-negative adults followed 2004-11
- Annual HIV prevalence and ART coverage in a 3km radius around each individual was calculated
- Hazard ratio for HIV seroconversion in relation to ART coverage calculated
 - Adjusted for gender, age, HIV prevalence and various HIV risk behaviours
- 1,413 seroconversions observed over 53,605 years of observation
 - Crude HIV incidence = 2.6/100 person-years




Increased ART coverage associated with reduced HIV incidence (dose-response relationship)




Tanser, Science 2013; 339: 966

Haiti trial Starting ART at <u>CD4<350</u> vs <u>CD4<200 or AIDS</u>



HR = 4.0



HR = 2.0

Early ART & IPT in HIV-Infected African Adults With High CD4 Count (Temprano Trial)

- Randomized 2x2 factorial superiority trial conducted in 9 HIV care centers in Côte d'Ivoire
 - Immediate ART vs WHO criteria
 - 6 months IPT vs no IPT
- March 2008 January 2015
- Inclusion criteria were:
 - HIV-1 infection
 - Age >18 years
 - CD4 nadir <800/ul
 - No criteria for starting ART according to the most recent WHO guidelines
- 2076 randomised; 2056 included in analysis (median CD4 = 465)

Severe morbidity	N	TAR (PY)	Rate (/100PY)	AHR	(95% CI)
Overall					
WHOART	111	2,247	4.94		
EarlyART	64	2,310	2.77	0.56	(0.41 - 0.76)
No IPT	104	2,225	4.67		
IPT	71	2,332	3.04	0.65	(0.48 - 0.88)
Baseline CD4 >500/ul					M
WHOART	38	918	4.14		
EarlyART	23	964	2.39	0.56	(0.33 - 0.93)
No IPT	37	918	4.03		
IPT	24	965	2.49	0.61	(0.37 - 1.02)

N: number of events. PY: person-years; TAR: time at risk; AHR: adjusted hazard ratio; CI: confidence interval

The primary endpoint was severe HIV morbidity (AIDS-defining diseases, non-AIDS-defining malignancy, or non-AIDS-defining invasive bacterial diseases), or any-cause mortality at 30 months .

START Study

<u>Strategic Timing of AntiRetroviral Treatment Study</u>

- Adult ART naïve patients with CD4 > 500
- Randomised to:
 - Immediate ART
 - Start when CD4 < 350</p>
- 215 sites in 35 countries
- 4,685 patients enrolled
- Due to end late 2016
- Stopped early by DSMB and results announced on 27 May 2015 (average 3 years follow-up)

NIAID Home	Health & Research Topics La	abs & Scientific Resources Funding About	NIAID News & Events
NAID > News & Events >	News Releases > 2015		
ews Releases		National Institute of Allergy and	Website Tools
2015	U.S. Department of Health and Human Services	Infectious Diseases (NIAID) http://www.niaid.nih.gov	Print this page
2014	📃 🛸 NIH News	http://www.naid.nin.gov	Add an RSS feed
2013	National Institutes of Health	h	🏁 Get email updates
2012	FOR IMMEDIATE RELEASE	Media Contact:	Order publications
Archive	Wednesday, May 27, 2015	NIAID Office of Communications	
Ву Торіс		(301) 402-1663 niaidnews@niaid.nih.gov	Related Links
		indianono eginaloriningo i	Media Contact Info
	Share this: 📑 📴 🧔 😰	+ Share	News by Topic
Starting Antiretroviral Treatmer		Treatment Early Improves Outcomes for	News From NIAID- Supported Institutions
	HIV-Infected Individuals		Health & Research Topics

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune system health—is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.

The new finding is from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, provided primary funding for the START trial. Though the study was expected to conclude at the end of 2016, an interim review of the study data by an independent data and safety monitoring board (DSMB) recommended that results be released early.

Event rate of primary endpoint

- Primary endpoint = AIDS, serious non-AIDS event* or death
- Early arm = 0.60/100 person years
- Deferred arm = 1.25/100 person years
- Hazard ratio = 0.47 (95%CI=0.32-0.68) (53% reduction in early arm)

^{*} Serious non-AIDS event = Major CVS, renal or hepatic disease or non-AIDS cancer

Table 1a. Number of primary endpoint in each arm (15 May 2015)

	Number of events		
	Number of events		
	Early arm (A)	Later arm (B)	
Category 1:AIDS, serious non-AIDS, or death (primary).	41	86	
Category 2:AIDS or AIDS death.	14	46	
Category 3:Serious non-AIDS or non-AIDS death.	28	41	


Tony Fauci (NIAID Director), 27 May 2015

"We now have clear-cut proof that it is of significantly greater health benefit to an HIV-infected person to start antiretroviral therapy sooner rather than later."


"Moreover, early therapy conveys a double benefit, not only improving the health of individuals but at the same time, by lowering their viral load, reducing the risk they will transmit HIV to others. These findings have global implications for the treatment of HIV."








Prioritise those with lowest CD4 counts Patients must be motivated for lifelong ART Fig. 5.1. Actual and projected numbers of people receiving antiretroviral therapy in low- and middle-income countries by WHO region and in high-income countries across WHO regions, 2003–2015^a




^aCountry income classification by the World Bank at the time of the 2011 Political Declaration on HIV and AIDS.

Source: Global AIDS Response Progress Reporting (WHO/UNICEF/UNAIDS)



People living with HIV who were on ART as a percentage of all people on ART in low- and middle-income countries

People living with HIV who were not on ART as a percentage of all people not on ART in low- and middle-income countries



Source: Global AIDS Response Progress Reporting (WHO/UNICEF/UNAIDS) and 2013 UNAIDS/WHO estimates.

By end of 2013

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

ART timing in patients with TB and CM

Timing of ART initiation

- ART should be started as soon as the patient is ready, and within at least 2 weeks of CD4 count being done
- In TB co-infection, start with TB treatment first, followed by ART as soon as possible and within 8 weeks
- If CD4 <50 cells/µl initiate ART within 2 weeks of starting TB treatment, when the patient's symptoms are improving and TB treatment is tolerated
- If CD4 >50 cells/µl initiate ART within 2-8 weeks of starting TB treatment
- In cryptococcal or TB meningitis: Defer ART initiation for 4-6 weeks

IMMEDIATE INITIATION: All HIV-positive pregnant or breastfeeding women, as long as no active TB

FAST TRACKING (within 7 days:)

- Patients with CD4 <200 cells/µl
- HIV stage 4, even if CD4 is not yet available

DOH guidelines


Randomised strategy trials of ART timing during TB treatment

Trial	Inclusion criteria	Early ART	Deferred ART
SAPiT* (South Africa)	Smear + PTB CD4 < 500	Within 4 weeks	8-12 weeks
STRIDE ACTG A5221 (Multi-country)	Smear + and – PTB CD4 < 250	Within 2 weeks	8-12 weeks
CAMELIA (Cambodia)	Smear + PTB and EPTB CD4 ≤ 200	2 weeks	8 weeks
TB meningitis trial (Vietnam)	TB meningitis	Within 1 week	8 weeks


* SAPiT had 3rd arm (ART within 4 weeks of completing TB treatment) that was stopped early by DSMB due to significant excess mortality

Abdool Karim NEJM 2011;365:1492, Havlir NEJM 2011;365:1482, Blanc NEJM 2011;365:1471, Torok Clin Infect Dis 2011;52:1374, Abdool Karim NEJM 2010;362:697

ART timing and primary endpoints




ART timing and primary endpoints in patients with CD4 < 50



* CAMELIA data represents all patients in trial, majority had CD4 < 50 (median CD4 = 25)


SAPiT IRIS incidence

(IRIS cases/100 person years)



TBM trial, Vietnam

Immediate ART (within 1 week) vs Deferred ART (8 weeks)



"These data support deferred initiation of ART in HIV-associated TBM, particularly in resource-limited settings"

Torok Clin Infect Dis 2011;52:1374

ART Timing in TB patients

- <u>CD4 < 50</u>
 - Start at 2 weeks
 - Increased TB-IRIS risk (2-5x)
 - PredART clinical trial evaluating prednisone to prevent TB-IRIS
- <u>CD4 > 50</u>
 - Can defer up to 8 weeks
 - Unless clinical reasons to start earlier
- <u>CD4 > 220</u>
 - Can defer longer but for programmatic reasons start by 8 weeks
- <u>TBM</u>
 - Defer 4-6 weeks

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis

David R. Boulware, M.D., M.P.H., David B. Meya, M.Med., Conrad Muzoora, M.Med., Melissa A. Rolfes, Ph.D., Katherine Huppler Hullsiek, Ph.D., Abdu Musubire, M.Med., Kabanda Taseera, M.Med., Henry W. Nabeta, M.B., Ch.B., Charlotte Schutz, M.B., Ch.B., M.P.H., Darlisha A. Williams, M.P.H.,
Radha Rajasingham, M.D., Joshua Rhein, M.D., Friedrich Thienemann, M.D., Ph.D., Melanie W. Lo, M.D., Kirsten Nielsen, Ph.D., Tracy L. Bergemann, Ph.D., Andrew Kambugu, M.Med., Yukari C. Manabe, M.D., Edward N. Janoff, M.D., Paul R. Bohjanen, M.D., Ph.D., Graeme Meintjes, M.B., Ch.B., Ph.D., for the COAT Trial Team*

N Engl J Med 2014;370:2487-98.


Randomized Strategy Trial Cryptococcal Optimal ART Timing (COAT) Trial Uganda and South Africa



Target enrollment = 500 177 participants enrolled Enrollment halted after 17 months by NIAID Africa DSMB

Boulware et al, NEJM 2014

Overall Survival



Recognised cryptococcal IRIS	<u>Sevents</u>
Early ART = $17/87$ (20%)	
Deferred ART = 9/69 (13%)	p=0.32

Boulware et al, NEJM 2014

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

First line ART

	1	2	3
Recommended	TDF	FTC/3TC	Efavirenz
Alternatives	ABC AZT Short term D4T	-	Rilpivirine Nevirapine

Raltegravir or PI/r to be used as 3rd drug when NNRTI contra-indicated eg. life-threatening hypersensitivity reaction

SA HIV Clinicians Society 2014

TDF and the kidney: Meta-analysis

- 17 studies
 - -9 RCT
 - 8 Observational
- Tenofovir vs other regimens
 - Mean difference in calculated CrCI: -3.9 ml/min
 - Risk difference for ARF: 0.7%
- But many studies exclude higher risk patients

First line ART & renal function

- Assess creatinine clearance at baseline
 - MDRD or modified Cockgraft-Gault formula
 - Avoid TDF if < 50ml/min</p>
 - Could later use TDF if normalises
- Monitor Creatinine on TDF
 - Timepoints: month 3, 6 and 12 then annually
 - If creatinine rises: recalculate creatinine clearance
- Generally avoid TDF while on injectable for MDR TB

The modified Cockroft-Gault equation:

Creatinine clearance = (140 - age) x ideal weight

serum creatinine

*For women, multiply the total by 0.85

NDOH 1st line if TDF contra-indicated

TDF contraindication:	ABC+ 3TC + EFV (or NVP)	Renal disease or the use of other
		nephrotoxic drugs e.g.
Creatinine clearance of		aminoglycosides
<50 mL/min		
		MDR treatment

Abacavir Drug Hypersensitivity (1)

- Features
 - Fever (usually 39-40 degrees)
 - Rash in 70% (maculopapular or urticarial)
 - Fatigue, malaise
 - GI symptoms (N&V, diarrhoea, abdominal pain)
 - Arthralgias
 - Cough, dyspnoea, pharyngitis
 - Usually > 1 system
 - Temporally related to taking dose
- Timing
 - Median onset 9 days
 - 90% in first 6 weeks

Abacavir Drug Hypersensitivity (2)

- Incidence
 - 4-8% in people of European descent
 - Much less common in people of African descent
 - Strongly associated with HLA-B5701
 - White Americans 8%
 - African-Americans 2.5%
 - Africa < 1%
- Can be fatal
 - 3/10,000 people on abacavir-based ART (trial data)
 - Rechallenge is an important risk

Use of Abacavir in 30 HIV-infected Children From Durban, South Africa

Report From a Pilot Study

To the Editors:

We report on the use of Abacavir from a pilot study conducted between February 3, 2004 and August 29, 2006 at King Edward VIII Hospital in Durban, South Africa. Ethical approval was obtained from the University of KwaZulu Natal.

Thirty ART (antiretroviral therapy) naive children aged between 2 and 12 years with vertically transmitted HIV-1 infection were enrolled in the study to assess the use of structured treatment interruptions.

The children received a combination of 3 nucleoside reverse transcriptase inhibitors, namely Zidovudine, Lamivudine, and Abacavir. The use of a triple nucleoside regimen was based on the unavailability of protease inhibitors at the time of the study, as well as on the possible risk of resistance developing if a non-nucleoside reverse transcriptase inhibitor was used in the interrupted subjects. ART was received for a mean of 84.27 wecks (2-96 wecks). Follow-up was done at regular intervals and the children were monitored for side effects. During the course of the study,

there were no significant adverse events. There was one instance of suspected hypersensitivity. This occurred in a 5-yearold child, who presented with fever and a rash 2 weeks after starting ART. A septic workup and skin biopsy were done on the child. All investigations were normal and the histopathology of the biopsy was nonspecific. It was therefore unclear whether the rash was drug related or due to an intercurrent viral infection. The rash cleared on stopping Abacavir and was therefore not recommenced. The child remained well on follow-up.

All children on the study had molecular class I HLA (human leukocyte antigen) typing done at baseline through the South African National Blood Bank. The most prevalent allele in this cohort was HLA-B*1503. No patient, including the child with the suspected hypersensitivity, had the HLA-B*5701 allele.

Abacavir has been recommended for use in both first and second line therapy.¹ However, there are safety concerns; as hypersensitivity to Abacavir can present with idiosyncratic symptoms.¹ Reintroduction can be potentially fatal. Studies have shown a strong associ-

ation between the presence of the (HLA) B*5701 allele and Abacavir hypersensitivity.¹ HLA-B*5701 is more prevalent among Caucasians.¹

In an HIV-1 infected clade C Zulu/ Xhosa population of both children and adults in Durban, South Africa, there was zero prevalence of "B5701.³⁻⁴ Prospective screening for HLA-B*5701 has a positive predictive value of 100% in preventing hypersensitivity reactions to Abacavir.¹ It has been suggested that patients be screened for possible hypersensitivity prior to treatment; however these tests are prohibitively expensive, and possibly not indicated in patients of African origin.

This is the first report on the use of Abacavir in African children. It appears to be safe in a population of children where the prevalence of HLA-B5701 is low, however, it would be prudent to maintain surveillance in view of some reports of Abacavir hypersensitivity in the absence of HLA-B $^{+}$ 701.⁵

Raziya Bobat, FCP(Paed), MD Gurpreet Kindra, MB BS, Dip(Epi) Department of Paediatrics and Child Health Nelson R Mandela School of Medicine

Photini Kiepiela, PhD Shabashini Reddy, BSc(Hons) HIV Pathogenesis Program Doris Duke Medical Research Institute

Prakash M. Jeena, FCP(Paed) Miriam Adhikari, FCP(Paed), MD Department of Paediatrics and Child Health Nelson R Mandela School of Medicine University of KwaZulu-Natal Congella, South Africa

Hoosen M. Coovadia, FCP(Paed), MD

HIV Pathogenesis Program Doris Duke Medical Research Institute University of KwaZulu Natal Durban, South Africa

REFERENCES

- Rabie H, Henning KL, Schoeman P, et al. Abacavir: its use and hypersensitivity. South Afr J HIV Med. 2009;10:81–84.
- Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. *Nature*. 2004;432:769–775.
- Thobakgale CF, Ramduth D, Reddy S, et al. Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants. J Virol. 2007;81:12775–12784.
- Thobakgale CF, Prendergast A, Crawford H, et al. Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. J Virol. 2009;83: 10234–10244.

J Antimicrob Chemother 2014; **69**: 3169–3180 doi:10.1093/jac/dku279 Advance Access publication 28 July 2014 Journal of Antimicrobial Chemotherapy

Virological efficacy of abacavir: systematic review and meta-analysis

Mario Cruciani¹*, Carlo Mengoli², Marina Malena¹, Giovanni Serpelloni¹, Saverio G. Parisi², Graeme Moyle³ and Oliviero Bosco¹

Findings

- In a meta-analytical pooling of RCTs with a direct comparison of ABC/3TC and TDF/FTC at 48 weeks (6 trials, 4118 patients) proportion with VL < 50 similar in
 - in overall comparison (RR 0.98; 95% CI 0.94–1.03),
 - in the low baseline VL strata (RR 1.01; 95% CI 0.99–1.03)
 - in the high baseline VL strata (RR 0.96; 95% CI 0.90–1.03)
- Similar virological results were found at 96 weeks (4 trials, 2003 patients)

48 weeks





Figure 4. Forest plot of comparison: rates of patients with VL <50 copies/mL at 48 weeks and 96 weeks in studies comparing abacavir (ABC) and tenofovir (TDF) according to baseline VL values. Cumulative results and subgroup analyses based on screening values: <100000 copies/mL (analyses 2.1.1 and 2.2.1) or >100000 copies/mL (analyses 2.1.2 and 2.2.2).

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

2nd line



If on rifampicin-based TB treatment: Double dose lopinavir/ritonavir

Contra-indication or Intolerance

Dyslipidaemia (total cholesterol >6 mmol/L) or diarrhoea associated with LPV/r	Switch LPV/r to ATV/r
Anaemia and renal failure	Switch to ABC

Atazanavir

- Causes <u>mild unconjugated</u> <u>hyperbilirubinaemia</u> in up to 50% of patients
- Competitive inhibition of uridine diphosphateglucuronosyl transferase (UGT) 1A1 enzyme similar to Gilbert's syndrome
- If other LFTs normal and no hepatitis symptoms then this does not represent liver injury
- Cannot be used with Rifampicin

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring


IPT guidelines

Table 13. Indications for and duration of IPT

TST	Pre-ART	On ART
Not done	IPT for 6 months	IPT for 12 months
Negative	IPT not indicated	IPT for 12 months
Positive	IPT for at least 36 months	IPT for at least 36 months
IPT = isoniazid preventive therapy; TST = tuberculin skin test; ART = antiretroviral therapy.		

SA HIV Clin Soc guidelines, 2014

Cochrane meta-analysis: IPT in HIV+



Akolo, 2010

Analysis 2.1. Comparison 2 Isoniazid vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).

Review: Treatment of latent tuberculosis infection in HIV infected persons

Comparison: 2 Isoniazid vs placebo


Outcome: I Incidence of active TB (confirmed, probable or possible)

Study or subgroup	Treatment (INH)	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
I PPD+					
Hawken 1997	5/67	8/69		6.3 %	0.64 [0.22, 1.87
Mwinga 1998	4/52	11/60		8.2 %	0.42 [0.14, 1.24
Pape 1993	2/38	6/25	· •	5.8 %	0.22 [0.05, 1.00
Whalen 1997	7/536	21/464		18.0 %	0.29 [0.12, 0.67
Subtotal (95% CI)	693	618	•	38.3 %	0.36 [0.22, 0.61]
Total events: 18 (Treatment (I	NH)), 46 (Control)				
Heterogeneity: $Chi^2 = 1.88$, d	$f = 3 (P = 0.60); I^2 = 0.0\%$				
Test for overall effect: $Z = 3.7$	8 (P = 0.00015)				
2 PPD-					
Fitzgerald 2001	6/126	4/111		3.4 %	1.32 [0.38, 4.56
Gordin 1997	4/260	6/257		4.8 %	0.66 [0.19, 2.31
Hawken 1997	11/235	8/224		6.6 %	1.31 [0.54, 3.20
Mwinga 1998	14/178	17/166		14.1 %	0.77 [0.39, 1.51
Pape 1993	2/20	5/35		2.9 %	0.70 [0.15, 3.28
Rivero 2003	3/83	4/77		3.3 %	0.70 [0.16, 3.01
Whalen 1997-anergy	9/395	10/323		8.8 %	0.74 [0.30, 1.79
Subtotal (95% CI)	1297	1193	+	43.9 %	0.86 [0.59, 1.26]
Total events: 49 (Treatment (I	NH)), 54 (Control)				
Heterogeneity: $Chi^2 = 1.87$, d	$f = 6 (P = 0.93); I^2 = 0.0\%$				
Test for overall effect: $Z = 0.7$	6 (P = 0.45)				
3 PPD unknown					
Hawken 1997	9/40	7/49		5.0 %	1.58 [0.64, 3.85
Mwinga 1998	9/122	16/124		12.7 %	0.57 [0.26, 1.24
Subtotal (95% CI)	162	173	-	17.7 %	0.86 [0.48, 1.52
Total events: 18 (Treatment (I	<i></i>				
Heterogeneity: Chi ² = 2.82, d					
Test for overall effect: $Z = 0.5$	3 (P = 0.59)				

Favours treatment Favours control

6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial

Taraz Samandari, Tefera B Agizew, Samba Nyirenda, Zegabriel Tedla, Thabisa Sibanda, Nong Shang, Barudi Mosimaneotsile, Oaitse I Motsamai, Lorna Bozeman, Margarett K Davis, Elizabeth A Talbot, Themba L Moeti, Howard J Moffat, Peter H Kilmarx, Kenneth G Castro, Charles D Wells



Overall (n=1995)

• 43% reduction in TB

TST positive

• 74% reduction in TB

TST negative

- No significant reduction in TB
- Unexplained increased mortality (21 vs 7 deaths after 5 months)

Lancet 2011; 377: 1588–98

Figure 2: Cumulative incidence of tuberculosis (A) and death (B) in participants receiving 6 months' open-label isoniazid and 30 months' masked placebo (control group) or isoniazid (continued isoniazid group)

Isoniazid plus antiretroviral therapy to prevent tuberculosis: (a randomised double-blind, placebo-controlled trial



Molebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, Judith R Glynn, Katherine Fielding, Gilles van Cutsem, Katalin A Wilkinson, Rene Goliath, Shaheed Mathee, Eric Goemaere, Gary Maartens

1329 patients starting ART/on ART randomised to 12 months IPT vs placebo





Figure 2: Time to tuberculosis from randomisation

The placebo group was given antiretroviral therapy plus placebo and the isoniazid group was given antiretroviral therapy plus isoniazid. Numbers show the number of participants followed up at each timepoint, and the numbers in parentheses show new tuberculosis cases in each period. Log-rank test p value for equality of survival curves=0.02.

Lancet, 2014



Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Metaanalysis of Observational Studies

Haileyesus Getahun¹*, Wanitchaya Kittikraisak², Charles M. Heilig³, Elizabeth L. Corbett⁴, Helen Ayles^{4,5}, Kevin P. Cain³, Alison D. Grant⁴, Gavin J. Churchyard⁶, Michael Kimerling⁷, Sarita Shah⁸, Stephen D. Lawn^{4,9}, Robin Wood⁹, Gary Maartens¹⁰, Reuben Granich¹, Anand A. Date³, Jay K. Varma^{2,3}

The best performing rule was the presence of any one of:


- current cough (any duration)
- fever
- night sweats
- or weight loss

The overall sensitivity was 78.9% and specificity was 49.6%

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

Phase of HIV management	Purpose
HIV diagnosis	
Confirm HIV result with rapid antibody test if no test results are available	To confirm HIV-positive status in patients who present without documented proof of positive HIV
	status
WHO clinical staging if HIV-positive	To assess eligibility for ART and timing of initiation
CD4 count	To identify eligibility for ART (CD4 <500/µI) To identify eligibility for prioritisation (CD4 <350/µI)
	To identify eligibility for fast-tracking (CD4 <200/µI) To identify eligibility for Cotrimoxazole (CD4 <200/µI)
	To identify eligibility for CrAg or CLAT (CD4 <100/µl)
Screen for pregnancy or ask if planning	To identify women who need ART for PMTCT and
to conceive	offer appropriate family planning
Assessment of hypertension and	To identify any concomitant chronic diseases
diabetes with blood pressure and urine	
glycosuria	
Screen for TB symptoms using the TB	To identify those suspected of TB and refer them for
screening tool	investigation and to assess eligibility for INH
Screen for HBV (HBsAg)	To identify those co-infected with HBV so that they can be initiated on ART regardless of CD4 count
Screening for STIs and syphilis	To identify and treat STIs
Weight and height in adolescent	To check if the weight is above or below 40kg to determine which ARV drugs to use
Cryptococcus Antigen (CrAg) test if CD4 <100 cells/µl	To assess if there is disseminated Cryptococcal infection and if fluconazole treatment/prophylaxis is indicated
Do Hb or FBC if requires AZT	To detect anaemia or neutropenia
Creatinine if requires TDF	To assess renal sufficiency
ALT if requires NVP	To exclude liver dysfunction
Fasting cholesterol and triglycerides if requires LPV/r	To identify at risk of LPV/r related hyperlipidaemia. If above 6 mml/L, consider (ATV/r) instead of LPV/r (if available)



In a Ugandan study: Antigenaemia preceded meningitis by median 22 days (>100 days in 11%)


French, AIDS 2002;16:1031

Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa


Joseph N. Jarvis,^{1,2,3,4} Stephen D. Lawn,^{1,5} Monica Vogt,¹ Nonzwakazi Bangani,¹ Robin Wood,¹ and Thomas S. Harrison^{1,4}

Clin Infect Dis 2009;48:856

Retrospective testing of plasma of 707 patients who started ART 2002-2005




Among those who were CrAg negative none developed CM



% of patients without prior CM who were CrAg +


Jarvis et al, Clin Infect Dis 2009;48:856




Cryptococcal Antigen Prevalence

Figure by: David Boulware

CrAg Lateral Flow Assay




Source: Immy CrAg LFA package insert



Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial

Sayoki Mfinanga, Duncan Chanda, Sokoine L Kivuyo, Lorna Guinness, Christian Bottomley, Victoria Simms, Carol Chijoka, Ayubu Masasi, Godfather Kimaro, Bernard Ngowi, Amos Kahwa, Peter Mwaba, Thomas S Harrison, Saidi Egwaga, Shabbar Jaffar, on behalf of the REMSTART trial team*

Lancet, published online March 10,2015



OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

Return to care after 1st line interruption

- Issues to consider
 - History of adherence prior to default episode
 - Viral load measure prior to default episode
 - CD4 nadir and current CD4
 - Current clinical status
- Individualised decision weighing up
 - Not wanting to unnecessarily switch to 2nd line (less well tolerated)
 - Not wanting to restart patient on failing regimen if very immunosuppressed
- If restart first line (especially in patients with CD4 < 200)
 - Do viral load when restart then at 2-3 months, anticipate > 2 log drop if adherent and no resistance
 - Most will have VL < 1000 by 3 months

Return to care after interruption (1)

- We recommend restarting the same regimen if patients return to care after defaulting therapy.
- A VL should preferably be performed before restarting. We then recommend that the VL is measured 3 months after restarting ART; switching to a second-line regimen should be considered if the VL is not <1 000 copies/mL at this point.
- In patients with multiple episodes of interruption, particularly beyond the first year of ART, many clinicians would consider switching to a second- line regimen, making the assumption that the multiple interruptions resulted in first-line resistance.
- Reasons for defaulting should be addressed and adherence support increased.

Return to care after interruption (2)

- Hospitalisation with an AIDS-defining condition and a CD4+ count of <50 cells/µL represents another situation where a patient may be restarted immediately on second-line ART when returning to care after defaulting
- The reason being that the patient is considered to be at high risk of mortality if restarted on a first-line therapy to which their virus may be resistant, and that they require a guaranteed effective ART regimen immediately.
- This decision should usually be taken by the clinicians at a hospital level.

6.6.9 Management of patients previously on ART

If a patient is referred in (e.g. from the private sector), and **is still on ART** and the regimen is successful (VL undetectable and no side-effects), where possible, the patient should be continued on the same regimen.

If the patient **has interrupted treatment** and was on a previous regimen as above, or where the prior regimen is unknown, take a full history to establish why the treatment was stopped. If the interruption was NOT due to toxicity or clear virological failure, check the VL and restart first line treatment as above, and **repeat the VL after 2 months.**

If patients have failed a previous regimen, initiate appropriate second line treatment.

If patient was **previously on ART but has interrupted treatment**, establish the cause of the interruption. If it is due to social or psychological factors, address these and follow up on interventions. If the patient stopped as a result of side effects, evaluate other drug choices and offer appropriate options. If the interruption was due to drug supply issues, and there were no non-adherence, resistance or toxicity issues, the previous ART regimen should be reinitiated as soon as possible.

NB: If NVP is restarted after an interruption of >1 week, re-commence with the 2 week lead-in dose and check the ALT if the patient becomes symptomatic.

SA NDOH guidelines

OUTLINE

- When to start ART
- ART timing in patients with TB and CM
- First line issues
- Second line issues
- IPT
- Cryptococcal antigen screening
- Return to care after ART interruption
- Reducing CD4 count monitoring

Monitoring on ART

On ART	Purpose
Screen for TB symptoms at each visit	To identify TB/HIV co-infected
WHO clinical staging at every visit	To identify new OIs
Ask about side effects at each visit	To identify ARV related toxicity
 CD4 at 1 year on ART	To monitor immune response to ART
VL at month 6, month 12 on ART and	To identify treatment failures and problems with
then every 12 months	adherence
ALT if on NVP and develops rash or	To identify NVP toxicity
symptoms of hepatitis	
FBC at month 3 and 6 if on AZT and	To identify AZT toxicity
then every 12 months	
Creatinine at month 3 and 6, month 12,	To identify TDF toxicity
then every 12 months if on TDF	
Fasting cholesterol and triglycerides at	To identify LPV/r toxicity
month 3 if on LPV/r	

Personal View

The future role of CD4 cell count for monitoring antiretroviral therapy



Nathan Ford, Graeme Meintjes, Anton Pozniak, Helen Bygrave, Andrew Hill, Trevor Peter, Mary-Ann Davies, Beatriz Grinsztejn, Alexandra Calmy, N Kumarasamy, Praphan Phanuphak, Pierre deBeaudrap, Marco Vitoria, Meg Doherty, Wendy Stevens, George K Siberry

For more than two decades, CD4 cell count measurements have been central to understanding HIV disease progression, making important clinical decisions, and monitoring the response to antiretroviral therapy (ART). In well resourced settings, the monitoring of patients on ART has been supported by routine virological monitoring. Viral load monitoring was recommended by WHO in 2013 guidelines as the preferred way to monitor people on ART, and efforts are underway to scale up access in resource-limited settings. Recent studies suggest that in situations where viral load is available and patients are virologically suppressed, long-term CD4 monitoring adds little value and stopping CD4 monitoring will have major cost savings. CD4 cell counts will continue to play an important part in initial decisions around ART initiation and clinical management, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted. However, in settings where both CD4 cell counts and viral load testing are routinely available, countries should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for patients who are stable on ART.


Lancet Infect Dis 2014

Published Online November 19, 2014 http://dx.doi.org/10.1016/ S1473-3099(14)70896-5

Department of HIV/AIDS, World Health Organization, Geneva, Switzerland (N Ford PhD, M Vitoria MD, M Doherty PhD); Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South

Consideration for Genotype & 3rd line

- Repeated VL > 1000 on 2nd line ART
- On 2nd line > 1 year
- Of those with virological failure on 2nd line majority do not have resistance*
- Critical to ensure adherence
 - Pharmacy claims records for the last 6 months is objective method (specific but not sensitive)
- Adherence counseling and address side effects
- Ask re previous exposure to rifampicin without lopinavir/ritonavir dose adjustment



Third line options

- NRTIs with best resistance profile
- New generation NNRTIs
 - Etravirine (and rilpivirine)
 - NNRTI genotype unreliable at 2nd line failure
- Ritonavir-boosted darunavir
- Raltegravir
- Maraviroc (cost+++, only if purely CCR5 tropic)
- Dolutegravir (to be registered later this year)

HIV DRUG RESISTANCE DATABASE

A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

GENOTYPE-RX

GENOTYPE-CLINICAL

HIVdb Program: Mutation List Analysis

Protease, RT, and integrase mutations can be entered using either the text box or pull down menus (detailed usage is found below).

The output can then be customized to display mutation comments, mutation scores, and an optional identifier and date. For further explanations and sample datasets please see the <u>Release Notes</u>.

Reverse Transcriptase	
Enter Mutation List:	1
OR	
Use The Pulldown Menus:	
41 44 62 65 67 69 70 74	🛟
75 77 90 98 100 101 103 106	🔹
108 + 115 + 116 + 118 + 138 + 151 + 179 + 181 (🛟
184 + 188 + 190 + 210 + 215 + 219 + 221 + 225	🛟
227 \$ 230 \$ 234 \$ 236 \$ 238 \$ 318 \$ 333 \$ 348	🛟
Protease	

http://hivdb.stanford.edu/

Mutation Scoring

PR	ATV/r I	DRV/r	FPV/r	IDV/r	LPV/r	NEV	SQV/r	TPV/r			
M46I	<u>10</u>	<u>0</u>	<u>10</u>		<u>10</u>	<u>20</u>	<u>5</u>	<u>5</u>			
154V	<u>15</u>	0	10		15	20	15	20			
L76V	<u>-5</u>	<u>20</u>	60	<u>30</u>	30	0	-5				
V82A	<u>15</u>	<u>0</u>	<u>15</u>	30	30	<u>30</u>	15	<u>0</u>			
L10IV	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>o</u> i	0	<u>0</u>	<u>0</u>			
Q58E	<u>5</u>	<u>0</u> 0	<u>0</u>	0	<u>0</u>	5	<u>0</u>	<u>15</u>	. 10 .01 .0		
A71I	<u>5</u>	<u>0</u>	<u>5</u>	<u>0</u>	<u>0</u>	5	<u>5</u>	<u>0</u>			
L76V+M46I		-!		10	10	10	-	•			
154V+V82A	10	-	10	10	10	10	10	-			
V82A+M46I	10		10	10	5	10	-!	-	•		
Total:	65	20	120	115	110	110	45	35			
RT		3TC A	ABC A	ZT D4	T DDI	FTC	TDF	FVF			PV
D67N		<u>0</u>	<u>5</u>		<u>5</u> <u>5</u>	•	<u>5</u>		-		_
T69DN	ł	<u>0</u>	<u>o</u>		0 30	<u>0</u>		 -	-		
K70R		<u>0</u>	10		5 10	•	2.4	_1	-	-	
M184V		<u>60</u>	15	· · · · ·	0 10		· · · · · ·		_		
K219Q		<u>0</u>	1		0 5		5	- i		_1	
A98G	•	-	-	-		-	-	10	10	30	15
								a of mark and frames			
F227L	-	-	- :	-!		-	·	<u>15</u>	0	<u>30</u>	<u>o</u> '
7N+K70R+K	219Q	10	10	10 1	0 10	10	10	-,		-	-
Total:		70	45	60 5	0 70	70	20	25	10	60	15
••••••••••••••••••••••••••••••••••••••	. 1			ale care		1	· · · ·			~~	

MUTATION SCORING

Mutation scoring

The mutation penalty score for an antiretroviral drug is obtained by adding together the scores of each mutation associated with resistance to that drug. The scores are titrated to fall within the following ranges:

- 0-9: Drug susceptible
- 10-14: Potential low level resistance
- 15-29: Low level resistance
- 30-59: Intermediate resistance
- >60: High level resistance

HIVdb: Genotypic Resistance Interpretation Algorithm

Report: Date: 18-Feb-2010 00:23:42 PST

Drug Resistance Interpretation: RT

NRTI Resistance Mutations:		M41L, K70R, Q1	51M	
NNRTI Resistance Mutations:		None		
Other Mutations:		None		
Nuc	leoside R	TI	Non-Nucl	eoside RTI
Iamivudine (3TC)Low-level resistarabacavir (ABC)Intermediate resistar		el resistance	delavirdine (DLV)	Susceptible
		diate resistance	efavirenz (EFV)	Susceptible
zidovudine (AZT)	High-lev	vel resistance	etravirine (ETR)	Susceptible
stavudine (D4T)	High-lev	vel resistance	nevirapine (NVP)	Susceptible
		vel resistance		
		el resistance		
tenofovir (TDF)	Interme	diate resistance		

RT Comments

NRTI

- M41L usually occurs with T215Y. Together these mutations confer intermediate-to-high level resistance to AZT and d4T and a lower level of resistance to ddl, ABC, and TDF.
- K70R causes low-level AZT, d4T, and possibly TDF resistance.
- By itself, Q151M causes intermediate-to-high level resistance to AZT, ddl, d4T, and ABC; and low-level
 resistance to TDF. With changes at the associated positions 75, 77, and 116, Q151M confers high-level
 resistance to AZT, ddl, d4T, and ABC; intermediate resistance to TDF, and low-level resistance to 3TC and
 FTC.

CASE 1: GT while failing 2nd line

Class	Mutations
NRTIS	M184V
NNRTIS	K103N
Pls	Mo major mutations

- Explanation?
- Management?

CASE 2: GT while failing 2nd line

Class	Mutations
NRTI	D67N, K70R, K219Q, M184V
NNRTI	A98G, F227L
PI	M46I, I54V, L76V, V82A, L10IV, Q85E, A71I

Mutation Scoring

PR	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	NFV	SQV/r	TPV/	r.		
M46I	<u>10</u>	<u>0</u>	10	<u>10</u>	10	<u>20</u>	<u>5</u>	Ę	5		
154V	<u>15</u>	0	10	e	the service states		15	1 .)		
L76V	-5	<u>20</u>	60	<u>30</u>	<u>30</u>	<u>0</u>	<u>-5</u>	-5	5		
V82A	<u>15</u>	<u>0</u>	<u>15</u>	<u>30</u>	30	<u>30</u>	<u>15</u>	<u>(</u>	<u>)</u>		
L10IV	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u> </u>	<u>)</u>		
Q58E	<u>5</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>5</u>	<u>0</u>	15	5		
A71I	<u>5</u>	<u>0</u>	<u>5</u>	<u>0</u>	<u>0</u>	<u>5</u>	<u>5</u>	<u>C</u>			
L76V+M46I	-	-	-	10	10	10	-		-		
154V+V82A	10	-	10	10	10	10	10	-	-		
V82A+M46I	10		10	10	5	10	-		•		
Total:	65	20	120	115	110	110	45	35	5		
RT		3TC A	ABCA	ZT	4T DD	FTC	TDF	EFV F	TR	NVP	RPV
D67N		<u>0</u>	<u>5</u>		<u>15</u>	•	1				· · · · · ·
T69DN		<u>0</u>	<u>o</u>		10 30	1			-	_	
K70R		<u>0</u>	<u>10</u>		15 10	·		_1			
M184V		60		• • •	10 10		1 1	_!			
K219Q		0	5		10 5		1	-		···· Ì	-
A98G		• .	-	-			-	10	10	30	15
		· · · · · · · · · · · · · · · · · · ·							, 0		
		· · · · · · · · · · · · · · · · · · ·						.	10	<u></u>	
F227L		-	_	- [-1	_ .	· ·	<u>15</u>	<u>0</u>		,
F227L 7N+K70R+K	219Q	- 10	- 10	-	_ 10 10	_ _); 10) 10		-	<u>30</u>	<u>0</u>

Management?

Management

• 3rd line:

– TDF/FTC + Raltegravir + Darunavir/ritonavir

- Follow-up viral loads:
 - Less than 40 for over 2 years

Efficacy of third line ART in Africa: outcomes on ART salvage regimens in the Southern African private sector

Liezl Dunn¹, Marla Coetsee¹, Michael Hislop¹, Leon Regensberg¹, Gary Maartens^{1,2}, <u>Graeme Meintjes^{1,2}</u>



¹Aid for AIDS ²University of Cape Town



7th EDCTP Forum, Berlin, 1 July 2014

Resistance patterns

185 resistance tests in 152 patients 111/113 were subtype C

Mutations	n	%
No TAMs	45	30%
1-2 TAMs	35	23%
≥ 3 TAMs	72	47%
No major PI mutations	0	0%
1-2 major PI mutations	38	25%
≥ 3 major PI mutations	114	75%


TAMs = Thymidine analogue mutations

Virological suppression


145 (95.4%) of 152 had at least one viral load performed on salvage ART

	n	% of those who had VL performed (n=145)	% of whole cohort (n=152)
Suppressed < 400	126	86.9%	82.9%
Suppressed < 50	108	74.5%	71.1%

CD4 count recovery on salvage ART (median and IQR)



Time on salvage ART (with +/- 3 month windows)



Vital status available for all patients on administrative censor date (30 April 2014)